In the past few years, a catheter-based technique has been developed for assessment of microvascular injury in the setting of AMI-namely, the index of microcirculatory resistance (IMR). 13 IMR is measured with a pressure sensor / thermistortipped guidewire and is calculated as mean distal coronary pressure × mean transit time of a 3-cc saline bolus measured during adenosine hyperemia. Fearon et al 13 demonstrated in 29 patients after primary percutaneous coronary intervention for AMI that IMR correlated significantly with 3-month postmyocardial infarction echocardiographic wall motion score and was its strongest predictor on multivariate analysis. IMR also predicted recovery of regional LV function.
In this issue of the Journal of the American Heart Association (JAHA), Payne et al 14 studied the use of this technique in a larger cohort (n=108) of post-AMI patients and compared the results with CMR studies at 2 days after AMI and 3 months after AMI. The authors are to be congratulated on the completion of this tour-de-force, which involved a large number of patients and 2 follow-up imaging studies, for which they had an 89% completion rate. They found that the measurement of IMR was extremely reproducible. IMR was a multivariate predictor of early myocardial salvage and predicted the presence and extent of microvascular obstruction and myocardial hemorrhage. In anterior myocardial infarction, IMR predicted late myocardial salvage. Thus, a catheter-based measurement in AMI can accurately assess the extent of microvascular injury while percutaneous coronary intervention is being performed, which is a potential way to obviate the need for further imaging of microvascular injury. Still, the correlations with 3-month ejection fraction and end-systolic volumes were modest and, in fact, fell out in multivariate models because IMR correlated much better with baseline measures of acute microvascular injury on CMR. This could have been, at least in part, because the infarct sizes were modest and ejection fractions fairly preserved, and thus the subsequent LV remodeling, which is dependent on initial infarct size, was likewise modest.
Several questions are raised by this interesting study. First, does the IMR measure add to what we already know at the time of intervention? The answer is a decided yes, given that measurement of Thrombolysis In Myocardial Infarction (TIMI) grade is an inadequate way of assessing microvascular function. Next, does IMR obviate performance of further imaging, such as CMR to assess the status of the microvasculature? This is a more difficult question to answer. Certainly, IMR adds to the understanding of myocardial physiology after reperfused myocardial infarction. One could ask, even though IMR correlated with the presence and extent of microvascular obstruction and myocardial hemorrhage, "Why not just perform the CMR and get a complete and definitive evaluation?" Certainly, cost and availability are issues with CMR. Not every hospital has CMR capability, and the additive cost of a study is not inconsequential. Payne et al 14 contend in the introduction to their article that CMR is "usually performed up to 7 days after hospital admission in medically stabilized patients." Perhaps that is true in Scotland. In the United States, hospital stays are generally on the order of 2 to 3 days after reperfused myocardial infarction, and thus CMR, if it is to be performed, must be obtained quite early on in the admission. It is safe to perform CMR even in the first 24 hours. Yet another question is, "Why was the correlation with subsequent LV remodeling less strong than the correlation with measures on the CMR at day 2?" What one would really like to have at the time of index evaluation is the ability to predict late outcomes over and above assessment of the current state of the myocardium.
The larger question is, "In which patients should microvascular function be assessed after reperfused AMI?" The issue here is that despite exhaustive studies over the past 3 decades, little progress has been made in mitigating reperfusion injury. Intravenous adenosine had some promise in that regard in the Acute Myocardial Infarction study of Adenosine (AMISTAD-II), in which infarct size was reduced with the higher dose and trends toward benefit were seen in larger anterior infarcts, 15 but further studies have not been performed since that publication. A multitude of other pharmacological agents have fallen by the wayside. Does it make sense to examine the microvasculature after AMI if we have no proven therapy to improve microvascular function and thus change subsequent LV remodeling and outcome? As it stands now, all post-AMI patients leave the hospital on 5 drugs, including aspirin, a statin, a β-blocker, an angiotensin-converting enzyme inhibitor, and clopidogrel-the latter if they received a stent as part of the percutaneous coronary intervention. No adjustments are made on the basis of the status of the microvasculature because these therapies are considered standard-of-care, and hospitals are monitored for adherence to this post-AMI medical regimen. Until such time as we have specific therapies for microvascular injury, it might not make sense to look for it, even though we have accurate ways to assess it with CMR and now IMR. Although the physiology is certainly of great interest, no method of assessing microvascular function after reperfused AMI has reached the current high bar of practicality and clinical utility.
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